These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16136504)

  • 1. The role of the bone marrow microenvironment in multiple myeloma.
    De Raeve HR; Vanderkerken K
    Histol Histopathol; 2005 Oct; 20(4):1227-50. PubMed ID: 16136504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
    Corso A; Ferretti E; Lazzarino M
    Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
    Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
    BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
    Asosingh K
    Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the bone marrow microenvironment in multiple myeloma.
    Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
    Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathogenesis of the bone disease of multiple myeloma.
    Edwards CM; Zhuang J; Mundy GR
    Bone; 2008 Jun; 42(6):1007-13. PubMed ID: 18406675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow microenvironment in multiple myeloma progression.
    Manier S; Sacco A; Leleu X; Ghobrial IM; Roccaro AM
    J Biomed Biotechnol; 2012; 2012():157496. PubMed ID: 23093834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma bone marrow niche.
    Basak GW; Srivastava AS; Malhotra R; Carrier E
    Curr Pharm Biotechnol; 2009 Apr; 10(3):345-6. PubMed ID: 19355944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.
    Giuliani N; Rizzoli V
    Leuk Lymphoma; 2007 Dec; 48(12):2323-9. PubMed ID: 18067006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.
    Li Y; Zheng Y; Li T; Wang Q; Qian J; Lu Y; Zhang M; Bi E; Yang M; Reu F; Yi Q; Cai Z
    Oncotarget; 2015 Sep; 6(27):24218-29. PubMed ID: 26155942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
    Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
    Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.
    Asosingh K; Günthert U; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
    Cancer Res; 2001 Apr; 61(7):2862-5. PubMed ID: 11306459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology and treatment of multiple myeloma.
    Tosi P; Gamberi B; Giuliani N
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):81-6. PubMed ID: 16399590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.